The online version of this article (doi:10.1186/1477-7819-10-104) contains supplementary material, which is available to authorized users.
The authors declare that there is no conflict of interest for this study.
Study concepts: XZ Study design: MG. Data acquisition: TX. A lgorithms: SW. Data analysis and interpretation: XZ, SG. Statistical analysis: YL, LL. Manuscript preparation: XZ, YY. Manuscript editing: XZ, MG. Manuscript review: MG. All authors read and approved the final manuscript.
Papillary thyroid carcinoma (PTC) is one of the most frequent endocrine malignancies. In most cases, it often presents as multifocal tumor. It has been reported that multifocal tumors are associated with elevated risk of lymph node and distant metastases. Multifocality is also one of the factors predicting prognosis. Recent studies show that BRAFV600E mutation occurs more frequently in aggressive PTC. The purpose of this study was to evaluate BRAFV600E status and clinicopathological features in multiple and solitary PTC.
We performed a retrospective study to analyze 512 PTC cases who received surgery, including 376 solitary PTCs and 136 multiple PTCs.
Multiple PTC is more related to lymph node metastasis and vascular invasion than solitary PTC. However, the distant metastasis rate and 10-year survival rate showed no difference between these two groups. BRAFV600E mutation status was more frequent in multiple PTC patients with lymph node metastasis and late stage at diagnosis.
BRAFV600E mutation is most commonly associated with extra-thyroidal extension and lymph node metastasis in PTC. Multiple PTC patients with young age, large tumors and BRAFV600E mutation should be followed carefully. Our study provides useful information for PTC patients’ followup and treatment.
Authors’ original file for figure 112957_2011_1018_MOESM1_ESM.pdf
Schlumberger MJ: Papillary and follicular thyroid carcinoma. N Eng J Med. 1998, 338: 297-306. 10.1056/NEJM199801293380506. CrossRef
Udelsman R, Chen H: The current management of thyroid cancer. Adv Surg. 1999, 33: 1-27. PubMed
Katoh R, Sasaki J, Kurihara H, Suzuki K, Iida Y, Kawaoi A: Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer. 1992, 70: 1585-1590. 10.1002/1097-0142(19920915)70:6<1585::AID-CNCR2820700623>3.0.CO;2-Z. CrossRefPubMed
Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL: Distinct multiple RET/PTC gene rearrangements in multiple papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998, 83: 4116-4122. 10.1210/jc.83.11.4116. PubMed
Hay ID, Grant CS, Van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ: Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992, 112: 1139-1146. discussion 1146–1137 PubMed
ItoK SuginoK, OzakiO MimuraT, IwasakiH ItoK: Papillary microcarcinoma of the thyroid. J Endocrinol Invest. 1998, 21: 445-448. CrossRef
Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003, 88: 5399-5404. 10.1210/jc.2003-030838. CrossRefPubMed
Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003, 63: 4561-4567. PubMed
Mazeh H, Samet Y, Hochstein D, Mizrahi I, Ariel I, Eid A, Freund HR: Multiple in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg. 2010, 9: 22-
Xiaoqi Lin, Finkelstein Sydney D, Bing Zhu, Silverman Jan F: Molecular analysis of multiple papillary thyroid carcinoma. J Mol Endocrinol. 2008, 41: 195-203. 10.1677/JME-08-0063. CrossRef
Nucera C, Goldfarb M, Hodin R: Role of B-Raf (V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf (V600E). Biochim Biophys Acta. 2009, 1795 (2): 152-161. PubMed
Kim TY, Kim WB, Rhee YS: The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2006, 65: 364-368. 10.1111/j.1365-2265.2006.02605.x. CrossRef
Howell Gina M, Carty Sally E, Armstrong Michaele J: Both BRAF V600E mutation and older age (>65 Years)are associated with recurrent papillary thyroid cancer. Ann Surg Oncol. 2011, 5: 19-
Trovisco V, Soares P, Preto A, de Vieira Castro I, Lima J, Castro P: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 2005, 446: 589-595. 10.1007/s00428-005-1236-0. CrossRefPubMed
- BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China
- BioMed Central
Neu im Fachgebiet Chirurgie
e.Med Kampagnen-Visual, Mail Icon II